



GF-TADs

GLOBAL FRAMEWORK FOR THE
PROGRESSIVE CONTROL OF
TRANSBOUNDARY ANIMAL DISEASES



Food and Agriculture
Organization of the
United Nations



World Organisation
for Animal Health
Founded as OIE

**Standing Group of Experts on Lumpy Skin Disease
in South East Europe
under the GF-TADs umbrella**

SGE LSD 12

2 March 2023

[Greece]

Country Update

Lumpy Skin Disease – Background information

- **LSD occurrence : 1st outbreak LSD on 20.08.2015 in the Regional Unit (RU) of Evros**

✓ *Number of outbreaks confirmed thereafter:*

✓ **2015: 117**

✓ **2016: 104**

✓ **2017: 1** in the **RU of Corfu** and **1** in the **RU of Karditsa**

Since then no outbreak has been reported

- **LSD Vaccination:** Vaccination campaign was initiated in **September 2015** from the **RU of Evros** and **was expanded in the whole Greek territory gradually, by 2016** and since then the project has been ongoing.
- **LSD surveillance (active) post vaccination:** Never



Lumpy Skin Disease – 2022 – Vaccination

- Number of bovine animals: **957.039 heads**
- Number of bovine animals vaccinated: **446.858 heads**
- Type of vaccine used: **LUMPYVAX (homologous)**
- Vaccination coverage: **56% (including immunized calves)**
- Type of animals vaccinated: **Bovine animals**
- Area where vaccination is carried out: **Whole territory**



Lumpy Skin Disease – 2022 – Surveillance

- Description of the active surveillance undertaken
- Active surveillance includes clinical examination of bovines for LSD in high risk areas of the country (regions of Eastern Macedonia and Thrace, Central Macedonia and Northern Aegean) in the framework of the Four (4) Exotic Diseases/Transboundary Diseases (TADs) Programme.

- ✓ number of herds examined:2.467
- ✓ number of animals examined :45.699
- ✓ types of animals examined :Bovines
- ✓ surveillance period: 2022
- ✓ **Negative results**




Lumpy Skin Disease – 2022 – Surveillance

- Clinical examination for LSD is also conducted in the framework of mandatory clinical examinations during the following activities throughout the year:
 - ✓ in all bovine animals before their vaccination for LSD (2022 : 446.858 heads),
 - ✓ in specific number of bovines in the framework of national control and eradication programmes for brucellosis, enzootic leukosis and tuberculosis,
 - ✓ in all bovine animals before their movement, a procedure verified with the Animal Health Certificate issued by the Local Veterinary Authorities and accompanying animals throughout transport (national legislation),
 - ✓ in all bovine animals during their ante mortem clinical examinations in slaughterhouses, including subsequent post mortem carcass inspections(2022 : 154.444 heads).
- **Negative results**
- **Description of the passive surveillance undertaken.**

Passive surveillance for Lumpy Skin Disease (LSD) is in place in the entire Greek territory and includes all bovine animals with symptoms compatible with LSD.

- For the year 2022 **no suspicion** was found.



Lumpy Skin Disease – 2023 – plans

- **LSD Vaccination:**

- Number of bovine animals: **935.976 heads**
- Number of bovine animals vaccinated: **935.976 heads**
- Type of vaccine used: **LUMPYVAX (homologous)**
- Type of animals vaccinated: **Bovine animals**
- Area where vaccination is carried out: **Whole territory**

- **LSD surveillance (active):**

Only clinical surveillance as in 2022



Lumpy Skin Disease – 2023 – plans

- **Other LSD measures :**

- **Renewal of contracts of seasonal personnel with the aim to contribute to the implementation of the vaccination program financed by national state-budget:**

2 employees at the National Reference Laboratory (NRL)

24 vets in specific RUs (depending on their vaccination percentage and permanent personnel deficiencies)

- **A Central procurement of the total amount of the vaccines was carried out by the Ministry of Rural Development and Food and it has already been allocated to Regional Units (600.000 doses for 2023).**

- **Corrective actions are also planned during 2023 :** (Teleconferences RUs with the lowest vaccination coverage/ intensive monitoring).



